ICON Public Limited (NASDAQ:ICLR) Short Interest Update

ICON Public Limited (NASDAQ:ICLR) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,390,000 shares, a drop of 13.7% from the January 15th total of 1,610,000 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily trading volume, of 1,130,000 shares, the short-interest ratio is presently 1.2 days.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. The Goldman Sachs Group reduced their price target on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Leerink Partners reissued an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Truist Financial dropped their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Citigroup lowered their target price on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, Barclays cut their target price on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ICON Public has an average rating of “Moderate Buy” and an average target price of $283.92.

Institutional Investors Weigh In On ICON Public

Hedge funds have recently made changes to their positions in the company. Natixis Advisors LLC grew its holdings in ICON Public by 6.7% during the 4th quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock worth $37,279,000 after acquiring an additional 11,177 shares in the last quarter. State of Tennessee Department of Treasury lifted its holdings in ICON Public by 1.0% during the fourth quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock worth $33,333,000 after buying an additional 1,600 shares during the period. Kornitzer Capital Management Inc. KS boosted its position in ICON Public by 40.6% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock valued at $20,363,000 after acquiring an additional 28,050 shares in the last quarter. Motley Fool Wealth Management LLC grew its stake in ICON Public by 2.3% in the fourth quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after purchasing an additional 1,466 shares during the last quarter. Finally, Foyston Gordon & Payne Inc lifted its position in shares of ICON Public by 27.3% during the fourth quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock valued at $10,845,000 after buying an additional 11,089 shares during the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Stock Performance

ICON Public stock opened at $186.21 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The company has a market capitalization of $15.36 billion, a PE ratio of 20.76, a P/E/G ratio of 1.78 and a beta of 1.19. The company has a 50 day moving average price of $204.18 and a 200-day moving average price of $247.73. ICON Public has a fifty-two week low of $181.51 and a fifty-two week high of $347.72.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.